Articles tagged with Tumor Necrosis Factors
A large study of nearly 60,000 patients with rheumatoid arthritis and other inflammatory diseases found that initiating anti-tumor necrosis factor therapies did not significantly increase the risk of herpes zoster. Corticosteroid use was associated with a higher risk of herpes zoster in this population.
A retrospective study published in Archives of Dermatology found that patients with psoriasis treated with tumor necrosis factor (TNF) inhibitors have a significantly lower risk of heart attack compared to those not treated with TNF inhibitors. The study included 8,845 patients and adjusted for other MI risk factors.
A phase I clinical trial confirms that a generic vaccine can kill autoimmune cells targeting insulin-secreting cells, temporarily restoring insulin production in patients with type 1 diabetes. The treatment pathway has been validated in humans and shows early evidence of effectiveness.
A new study suggests that chronic exposure to artificial light at night can lead to depressive symptoms in rodents, which can be reversed by returning to a standard light-dark cycle. The study found that blocking the effects of tumor necrosis factor, a protein involved in depression, prevented the development of depressive-like symptoms.
A study found that children with juvenile idiopathic arthritis have a higher risk of hospitalized bacterial infections than children without the condition. High-dose steroids significantly increased this risk, while methotrexate and tumor necrosis factor inhibitors did not.
Research finds that children with JIA have a significantly increased cancer risk, with rates 3.9 times higher for methotrexate-only patients and 4.4 times higher overall compared to peers without the disease. The study suggests that treatment, including TNF inhibitors, may not be directly linked to this increased risk.
A new study has discovered a way to prevent septic shock by blocking a specific form of cell death called necroptosis. The approach fully protects mice against the fatal inflammation, offering a potential new target for therapy. Researchers found that eliminating RIPK molecules led to full protection against sepsis.
A new study found that inhibiting necroptosis protects mice from lethal sepsis by blocking a specific cell death pathway. The research may lead to new therapeutic interventions for fatal inflammatory conditions.
Researchers from Johns Hopkins have quantified a cell's decision-making ability, finding it to be only two possible choices. Cells can overcome their individual limitations by forming multicellular organisms, which enables them to transfer information and make decisions together.
A systematic review and meta-analysis of 21 studies found that biological agents for rheumatoid arthritis may increase the risk of skin cancer. The pooled risk showed a 45% higher likelihood of developing other types of skin cancer, while two studies indicated a 79% increased risk of melanoma.
A study of nearly 14,000 patients with rheumatoid arthritis or psoriasis found that certain disease-modifying antirheumatic drugs reduced the risk of developing type 2 diabetes. The findings suggest a possible role for immunosuppression in preventing diabetes among patients with systemic inflammatory disorders.
A recent study published in Nature Immunology has discovered a novel mechanism by which tumor necrosis factor (TNF) suppresses inflammatory responses. The researchers found that TNF activates the glycogen synthase kinase 3-alpha protein and upregulates the A20 gene, leading to reduced inflammation.
Increasing rates of drug-resistant TB pose a significant threat to global progress in controlling the disease. The growing burden of TB is also linked to other risk factors like smoking and diabetes, which increase the risk of contracting the disease by two- and three-fold, respectively.
A recent trial found the combination of rituximab, a TNF inhibitor, and methotrexate showed a consistent safety profile for rheumatoid arthritis patients. While no new safety concerns were identified, clear efficacy benefits were not observed in this study sample.
Scientists discovered that mitochondria, cell energy factories, produce reactive oxygen species (ROS) causing uncontrolled inflammation in TRAPS. Blocking ROS may reduce inflammation in this disorder and possibly other inflammatory diseases.
Current smokers with early rheumatoid arthritis showed reduced response to treatment with methotrexate and tumor necrosis factor inhibitors. The study found that smoking history did not impact the effectiveness of these therapies.
A new study found that childhood abuse can lead to a weakened immune system later in life, with participants who experienced adverse experiences showing higher levels of stress markers. Additionally, caregivers who had been abused as children showed significantly shorter telomere length than non-caregivers.
A study conducted by University at Buffalo researchers found that resveratrol suppressed the generation of free radicals and reduced inflammation in human blood samples. The compound also showed promise in reducing insulin resistance and related markers, potentially benefiting conditions like type 2 diabetes and heart disease.
A study by FDA researchers found a higher incidence of malignancy in children using TNF blockers like infliximab and etanercept. The reporting rate for U.S. cases of malignancy in children was 4-18 times the estimated background rate for the general pediatric population.
Researchers at Medical College of Georgia have developed a synthetic peptide that mimics the body's natural ability to reduce excess fluid accumulation in lung transplant patients. The peptide, called TIP, has been shown to improve oxygenation and reduce inflammation, potentially reducing mortality rates.
A study by NC State researchers found that a protein called TAB2 activates inflammation but also brings together molecules to turn it off. This finding challenges previous understanding of the protein's role in immune-system responses.
A new study published in The Lancet found that adding a TNF antagonist like infliximab to methotrexate treatment improves symptoms for patients with early rheumatoid arthritis who have not responded well to methotrexate alone. This approach can prevent overtreatment and reduce side effects and costs.
Using precise microscopes, University of Missouri researchers identified tumor necrosis factor-α and advanced glycation end products as major contributors to blood vessel dysfunction in type 2 diabetes. This discovery could lead to new treatments for blood vessel diseases and disorders in people with type 2 diabetes.
Researchers at MGH confirmed a potential new therapy for type 1 diabetes by selectively killing autoimmune cells in human patients. The treatment, which blocks a metabolic pathway regulating the immune system, eliminates immune cells that react against a patient's own tissues.
Researchers have identified Smurf1 as a signaling partner that damages bone in rheumatoid arthritis, guiding the development of new drugs to reverse bone loss. The study also suggests potential applications against osteoporosis by targeting Smurf1 with specific drugs.
Researchers from NIAMS identified a promising new target for autoimmune disease treatment, a cell-surface receptor called DR3. Blocking this receptor could slow or stop damaging inflammation characteristic of autoimmune diseases without leaving the body vulnerable to serious infections.
Researchers at Hospital for Special Surgery discovered a new mechanism involved in the pathogenesis of inflammatory diseases such as rheumatoid arthritis. The study reveals that tumor necrosis factor (TNF) activates macrophages to produce interferon-beta, leading to sustained expression of genes encoding inflammatory molecules.
Researchers found that Enbrel significantly reduced levels of C-reactive protein in patients with moderate to severe plaque psoriasis, indicating a systemic inflammatory disease. The study also showed that heavier patients had higher CRP levels and that Enbrel decreased these levels in overweight and obese patients.
A recent clinical trial demonstrated that 50% of patients with active early rheumatoid arthritis achieved clinical remission after one year of treatment with ENBREL plus methotrexate. The study also showed significant improvements in symptoms and joint damage, setting a new standard for earlier treatment of RA.
Researchers found that platelets' GPIIb/IIIa receptors stimulate neutrophils to produce TNF, a key inflammatory compound. This discovery may lead to the development of new anti-inflammatory drugs targeting these receptors.
A phase 3 randomized trial found that extended exposure to etanercept improved measures of disease severity in patients with moderate to severe psoriasis. The treatment was well-tolerated, with no increased risk of adverse events or infections.
A study of long-term Enbrel use found a consistent safety profile in patients with moderate-to-severe juvenile rheumatoid arthritis. Sixty-one percent of patients completed four years of therapy, and 38% reached eight years without significant adverse effects.
A newly identified immunosuppressive protein, decoy receptor 3 (DcR3), is expressed in rheumatoid synovial fibroblasts and protects them from apoptosis. DcR3's expression is increased by TNFα, contributing to the excessive growth of synovial tissue in RA.
Researchers found that breast-feeding counters genetic tendencies toward ear infections, which can lead to learning difficulties and language development issues. The study identified specific genes involved in the vulnerability, but found that breast-feeding effectively neutralized their impact.
Patients with ankylosing spondylitis who received Enbrel treatment experienced sustained improvements in signs and symptoms, spinal mobility, and physical function over 148-160 weeks. A total of 78% of patients achieved a 20% improvement in the Assessment on Ankylosing Spondylitis Response Criteria (ASAS) after 160 weeks.
Enbrel, a biologic treatment, demonstrates sustained improvements in rheumatoid arthritis symptoms over up to nine years. Patients showed significant reductions in joint pain, stiffness, and disability.
Dr. Kevin J. Tracey's theory of the inflammatory reflex reveals a direct link between brain and immune system via the vagus nerve, providing a new approach to treating chronic inflammatory diseases. By manipulating brain activity, individuals may be able to 'think' their way to feeling better.
UT Southwestern researchers found that blocking tumor necrosis factor, an inflammatory molecule, reduces dopamine neuron death in rats with Parkinson's disease. The study suggests that TNF-dependent inflammation may contribute to the progression of the disease.
New research suggests that treatment with TNF inhibitors reduces cardiovascular events, including myocardial infarction and cerebrovascular accidents, in rheumatoid arthritis patients. However, a separate study found an increased risk of serious infections in patients treated with TNF inhibitors.
Rituximab plus methotrexate treatment significantly inhibits joint structural damage, reducing bone erosions and joint space narrowing in patients. The study's findings offer new hope for those who do not respond to current treatments.
A study found that blocking key protein etanercept reduced inflammatory markers in patients with metabolic syndrome, a condition characterized by abdominal obesity, high triglycerides, and low HDL cholesterol. The treatment also showed promise in reducing cardiovascular risk factors.
A computer model developed by Johns Hopkins researchers could help produce medications that regulate immune response levels, potentially treating septic shock, cancer, lupus, and rheumatoid arthritis. The study focused on how a protein molecule called tumor necrosis factor triggers an immune response.
Researchers found that patients with elevated tumor necrosis factor (TNF) levels at seven days post-transplant were more likely to develop graft vs. host disease and had lower one-year survival rates. Elevated TNF levels were tied to a higher risk of this deadly complication, suggesting potential targets for prevention and treatment.
A California-based study found that genetic susceptibility caused by a variant genotype influences the risk of respiratory-related school absences due to second-hand smoke. Exposure to second-hand smoke increased the risk by 51% for lower respiratory illness in genetically susceptible children.
The TEMPO study demonstrated that over three-quarters of patients treated with Enbrel plus methotrexate experienced no progression of joint damage. Additionally, patients treated with this combination therapy showed a significant improvement in physical function compared to those receiving either treatment alone.
Researchers investigated tumour necrosis factor alpha, finding higher levels in severe asthmatics with chronic disease resistant to steroid treatment. A treatment using a TNF-alpha blocking drug improved symptoms and lung function in patients with severe asthma.
The study found a cellular protein called HVEM acts as an 'off and on switch' for immune responses, enabling communication between T lymphocytes and other cells. This discovery could lead to new treatments for autoimmune diseases by mimicking HVEM's action.
Researchers found TNF inhibits conversion of DHEAS to DHEA, leading to local androgen deficiency in RA patients. The study highlights the need for early anti-TNF antibody therapy in treating this inflammatory disease.
Research reveals Interleukin-6 has various roles in metabolic gene activation, lipolysis, insulin resistance inhibition and TNF suppression. The cytokine's diverse effects make it a promising therapeutic target for treating obesity, type 2 diabetes and other metabolic disorders.
Researchers developed novel proteins that can block the activation of tumor necrosis factor (TNF), a key regulator of inflammation in rheumatoid arthritis. These modified versions of TNF are designed to prevent an immune response, offering a promising new avenue for treating the disease.
In a global, double-blind, placebo-controlled study, ENBREL demonstrated significant improvements in Psoriasis Area and Severity Index (PASI 75) scores after 12 weeks of treatment. Nearly half of patients treated with 50mg or 25mg of ENBREL twice weekly achieved PASI 75 versus 3% of placebo-treated patients.
Researchers developed a gene therapy combining radiation therapy and cisplatin to target tumor cells, resulting in significant regression with no additional toxicity. The treatment uses a modified cold virus to insert the TNF gene into tumor cells, enhancing anti-cancer effects.
Phase 3 results of ENBREL (etanercept) demonstrated significant improvement in signs and symptoms of psoriatic arthritis, with 72% of patients experiencing treatment response after 12 weeks. The study also showed improvements in skin manifestations and psoriasis activity.
A Phase 2 double-blind, placebo-controlled study found that 40 patients with ankylosing spondylitis achieved a significant clinical response when treated with ENBREL (etanercept), with 80% of patients showing improvement in outcome measures. The treatment was generally well-tolerated with no serious adverse events or withdrawals.
A team of UNC researchers has made a significant discovery about the role of tumor necrosis factor-alpha in remyelination, the process by which nerve cells regain their natural fatty sheath. The study found that this cytokine plays a critical role in white matter repair and induces the production of nerve precursor cells.
The RANKL cytokine at 2.6 Å resolution provides detailed information on its structure and function in the body. Researchers used this high-resolution imaging technique to study RANKL's role in bone formation and immune system regulation.
Researchers found that infliximab treatment reduced ocular inflammation and symptoms in patients with Behcet's disease, including those at risk of permanent blindness. The study suggests TNF blockade as a new therapy for sight-threatening uveitis and severe vasculitic manifestations.
A20 is a critical regulator of inflammation in multiple tissues, protecting against damage by inhibiting TNF activation. The discovery suggests new ways to block inflammation and may lead to novel forms of therapy for conditions like ulcerative colitis and septic shock.
Scientists have discovered that activation of NF-kappa B prevents expression of a key regulatory protein called MyoD from replenishing muscle tissue. This finding has significant implications for treating cachexia, a syndrome that kills an estimated one third of cancer patients.
A recent study by Ohio State University researchers found that a chemical called tumor necrosis factor (TNF) directly stimulates the brain's digestive control center, causing nausea and vomiting. Elevated TNF levels can lead to long-term changes in digestion function, resulting in persistent symptoms.